#United States #Canton #Kelyniam Global #cranial implants #private investment

Kelyniam Global Announces Successful PIPE Closure

Kelyniam Global, Inc. (OTC: KLYG), known for its innovative custom cranial implants, has officially completed a successful private investment in public equity (PIPE) closure aimed at accelerating its growth objectives for the year 2025. The offering, which closed its period on November 30, 2024, has attracted several accredited investors without the involvement of a placement agent, highlighting the confidence shareholders have in the company's strategic direction.

The proceeds from the sale of restricted shares of Kelyniam’s common stock are earmarked for several critical investments. These include enhancing sales and marketing initiatives for both existing and upcoming products, covering regulatory and FDA filing fees for new product launches, and facilitating geographical expansion into various territories throughout the United States. This expansion will focus particularly on trauma centers and neurology-focused medical facilities, aligning with Kelyniam's mission to improve clinical outcomes through advanced medical technology.

Ross Bjella, CEO of Kelyniam, expressed satisfaction with the strong performance of the business over the first three quarters of the year. He noted, “I am pleased that our shareholders continue to express confidence in the strategic direction of Kelyniam. We aim to deploy these funds wisely to build scale across all our distribution channels and enhance our geographical footprint in 2025 and beyond.” This proactive approach demonstrates Kelyniam's commitment to driving growth while meeting the needs of healthcare providers and patients alike.

Kelyniam Global specializes in the rapid production of custom prosthetics, leveraging cutting-edge computer-aided design and manufacturing technologies utilizing advanced medical-grade polymers. By working directly with surgeons and health systems, Kelyniam strives to generate significant improvements in both clinical and cost-efficiency outcomes.

As a cautionary note to investors, Kelyniam has indicated that certain statements in this announcement could be seen as forward-looking, subject to the risks and uncertainties associated with market conditions, competitive factors, and the company's ability to execute its business plans effectively.

For interested stakeholders, more information can be found on Kelyniam’s official website at www.Kelyniam.com. The company aims to provide updates on its ongoing development and operational strategies as it positions itself for strengthened performance and expanded market presence in the near future.